VIVES is a multi-sector fund that invests in projects with a positive societal impact
A-Mansia is the first co-spin-off resulting from joint research conducted at two European universities, the Catholic University of Louvain (Belgium) and the University of Wageningen (the Netherlands)....
Emolytics is a spin-off company of UCLouvain (Belgium) which is closely supported by the Louvain Technology Transfer Office. The technology originated in the University's research center in 2009 as a...
Olygose, located in France, was created in 2009. Its ambition is to develop, produce and market innovative prebiotic ingredients:
• Plant-derived by-product extract
• Use unique extraction and...
Pierre-Antoine Mariage, co-CEO Botalys :
"VIVES trusted us at an early stage. In addition to their financial investment, they offer us a regular and wise coaching from their experts while respecting...
Georges Caron, past CEO Keemotion :
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with...
Denis Périquet, CEO Tessares :
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
- Proposer Des Thérapies Cellulaires Innovantes Axées Sur Le Foie Pour Le Marché Japonais -
Promethera® Biosciences SA ("Promethera®") et MEDIPAL HOLDINGS CORP. ("MEDIPAL") ont annoncé aujourd’hui la
Belgique - 5 novembre 2019 - Syndesi Therapeutics SA, une société de biotechnologie développant de nouveaux modulateurs de la protéine de vésicule synaptique SV2A pour le traitement de la déficience
L’étude met en avant les avantages potentiels de ce traitement pour les troubles orthopédiques rares chez l'enfant.
Mont-Saint-Guibert, Belgique, le 2 octobre 2019 : Novadip Biosciences («Novadip» ou